$IMNM
Immunome Inc.

2021 Q1 Form 10-Q Financial Statement

#000155837021006858 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.920M $2.240M
YoY Change 46.89%
% of Gross Profit
Research & Development $1.979M $1.840M $2.115M
YoY Change -6.43% -79.15%
% of Gross Profit
Depreciation & Amortization $176.0K $260.0K $163.0K
YoY Change 7.98% -18.75%
% of Gross Profit
Operating Expenses $3.897M $4.070M $2.655M
YoY Change 46.78% -60.67%
Operating Profit -$3.897M -$2.655M
YoY Change 46.78%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.900M -$4.070M
YoY Change -61.03%
Income Tax
% Of Pretax Income
Net Earnings -$3.900M -$4.070M -$2.700M
YoY Change 44.44% -61.03%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37
Diluted Earnings Per Share -$0.37 -$381.8K
COMMON SHARES
Basic Shares Outstanding 10.64M 10.54M
Diluted Shares Outstanding 10.64M

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.28M $39.77M
YoY Change
Cash & Equivalents $36.28M $39.77M $1.368M
Short-Term Investments
Other Short-Term Assets $4.830M $3.130M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $41.11M $42.89M
YoY Change 1273.93%
LONG-TERM ASSETS
Property, Plant & Equipment $1.386M $1.531M
YoY Change -9.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K
YoY Change -27.54%
Total Long-Term Assets $1.486M $1.631M
YoY Change -15.84%
TOTAL ASSETS
Total Short-Term Assets $41.11M $42.89M
Total Long-Term Assets $1.486M $1.631M
Total Assets $42.59M $44.53M
YoY Change 779.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.958M $1.187M
YoY Change 116.61%
Accrued Expenses $1.169M $1.372M
YoY Change 106.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $366.0K $366.0K
YoY Change
Total Short-Term Liabilities $4.571M $3.038M
YoY Change 82.46%
LONG-TERM LIABILITIES
Long-Term Debt $134.0K $134.0K
YoY Change
Other Long-Term Liabilities $10.00K $10.00K
YoY Change
Total Long-Term Liabilities $134.0K $134.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.571M $3.038M
Total Long-Term Liabilities $134.0K $134.0K
Total Liabilities $4.710M $3.180M
YoY Change 77.06%
SHAREHOLDERS EQUITY
Retained Earnings -$58.30M -$54.40M
YoY Change 48.63%
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.88M $41.35M -$38.16M
YoY Change
Total Liabilities & Shareholders Equity $42.59M $44.53M
YoY Change 779.94%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q1
OPERATING ACTIVITIES
Net Income -$3.900M -$4.070M -$2.700M
YoY Change 44.44% -61.03%
Depreciation, Depletion And Amortization $176.0K $260.0K $163.0K
YoY Change 7.98% -18.75%
Cash From Operating Activities -$3.535M -$6.060M -$2.064M
YoY Change 71.27% 22.67%
INVESTING ACTIVITIES
Capital Expenditures $31.00K -$50.00K $55.00K
YoY Change -43.64% -73.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$31.00K -$50.00K -$55.00K
YoY Change -43.64% -73.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $105.0K $41.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 76.00K 39.13M 844.0K
YoY Change -91.0% 785.29%
NET CHANGE
Cash From Operating Activities -3.535M -6.060M -2.064M
Cash From Investing Activities -31.00K -50.00K -55.00K
Cash From Financing Activities 76.00K 39.13M 844.0K
Net Change In Cash -3.490M 33.02M -1.275M
YoY Change 173.73% -4750.7%
FREE CASH FLOW
Cash From Operating Activities -$3.535M -$6.060M -$2.064M
Capital Expenditures $31.00K -$50.00K $55.00K
Free Cash Flow -$3.566M -$6.010M -$2.119M
YoY Change 68.29% 26.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001472012
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1372000
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1667
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y7M9D
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10660181
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10634245
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-39580
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Immunome, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
CY2021Q1 dei City Area Code
CityAreaCode
610
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
321-3700
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2021Q1 dei Trading Symbol
TradingSymbol
IMNM
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11757255
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36276000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39766000
CY2021Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4831000
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3128000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
41107000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
42894000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1386000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1531000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q1 us-gaap Assets
Assets
42593000
CY2020Q4 us-gaap Assets
Assets
44525000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
366000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
366000
CY2021Q1 imnm Current Portion Of Equipment Loan Payable
CurrentPortionOfEquipmentLoanPayable
78000
CY2020Q4 imnm Current Portion Of Equipment Loan Payable
CurrentPortionOfEquipmentLoanPayable
113000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2958000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1187000
CY2021Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1169000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4571000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3038000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
134000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
134000
CY2021Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8000
CY2021Q1 us-gaap Liabilities
Liabilities
4710000
CY2020Q4 us-gaap Liabilities
Liabilities
3180000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10660181
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10634245
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96174000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95738000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58292000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54394000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
37883000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42593000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44525000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1979000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2115000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1918000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
540000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
3897000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
2655000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3897000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2655000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1000
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-22000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3898000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2677000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.44
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10640870
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1099270
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
325000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
105000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3898000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
37883000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-35630000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2677000
CY2020Q1 imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
55000
CY2020Q1 imnm Repayments Of Capital Lease Obligations
RepaymentsOfCapitalLeaseObligations
96000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
76000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
844000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3490000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1275000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2643000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36376000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1368000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-38161000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3898000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2677000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
176000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
163000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
325000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
146000
CY2021Q1 imnm Deferred Rent
DeferredRent
-1000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1703000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-99000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1771000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
314000
CY2021Q1 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-205000
CY2020Q1 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-109000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3535000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2064000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55000
CY2020Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
995000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
105000
CY2021Q1 imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
35000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
13000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3900000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2700000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58300000
CY2020Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41700000
CY2020Q4 imnm Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
3100000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the fair value of the Company’s common stock in connection with share-based compensation arrangements. Actual results could differ from these estimates.</p>
CY2021Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020Q1 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2021Q1 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2659599
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5464615
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
667000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
255000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
845000
CY2021Q1 imnm Professional Fees Contractors And Other Liabilities Current
ProfessionalFeesContractorsAndOtherLiabilitiesCurrent
247000
CY2020Q4 imnm Professional Fees Contractors And Other Liabilities Current
ProfessionalFeesContractorsAndOtherLiabilitiesCurrent
527000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1169000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1372000
us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
monthly
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
146000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7300000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
366000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
134000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
500000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
366000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
134000
CY2020Q1 us-gaap Payments For Rent
PaymentsForRent
100000
CY2021Q1 us-gaap Payments For Rent
PaymentsForRent
100000
CY2021Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
39000
CY2020Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
16000
CY2021Q1 imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
325000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.835
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.800
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.008
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2021Q1 imnm Fair Value Of Common Stock
FairValueOfCommonStock
31.83
CY2020Q1 imnm Fair Value Of Common Stock
FairValueOfCommonStock
1.62
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
8.69

Files In Submission

Name View Source Status
0001558370-21-006858-index-headers.html Edgar Link pending
0001558370-21-006858-index.html Edgar Link pending
0001558370-21-006858.txt Edgar Link pending
0001558370-21-006858-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20210331.xsd Edgar Link pending
tmb-20210331x10q.htm Edgar Link pending
tmb-20210331x10q_htm.xml Edgar Link completed
tmb-20210331xex31d1.htm Edgar Link pending
tmb-20210331xex31d2.htm Edgar Link pending
tmb-20210331xex32d1.htm Edgar Link pending
tmb-20210331xex32d2.htm Edgar Link pending
tmb-20210331_cal.xml Edgar Link unprocessable
tmb-20210331_def.xml Edgar Link unprocessable
tmb-20210331_lab.xml Edgar Link unprocessable
tmb-20210331_pre.xml Edgar Link unprocessable